NCT00979251 - Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

August 31, 2011

Conditions

Influenza

Interventions

DRUG

Oseltamivir Phosphate

Oseltamivir Phosphate, q8h

DRUG

ADS-8902

Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h

Trial Locations (25)

3050

Adamas Investigative Site, Parkville

38105

Adamas Investigational Site, Memphis

57702

Adamas Investigational Site, Rapid City

94114

Adamas Investigational Site, San Francisco

94115

Adamas Investigational Site, San Francisco

Unknown

Adamas Investigational Site, San Francisco

Adamas Investigational Site, Hollywood

Adamas Investigational Site, Miramar

Adamas Investigational Site, Pinellas Park

Adamas Investigational Site, Honolulu

Adamas Investigational Site, Owensboro

Adamas Investigational Site, New Orleans

Adamas Investigational Site, Las Vegas

Adamas Investigational Site, New York

Adamas Investigational Site, Amarillo

Adamas Investigational Site, Seattle

Adamas Investigational Site, Tacoma

Adamas Investigational Site, Melbourne

Adamas Investigational Site, Edmonton

Adamas Investigational Site, Toronto

Adamas Investigational Site, Leiden

Adamas Investigational Site, Singapore

NSW 2010

Adamas Investigational Site, Darlinghurst

QLD 4029

Adamas Investigational Site, Herston

Adamas Investigational Site, Sydney